RYBREVANT FASPRO
LaunchBsAbBLASINGLE-USEVIAL
Approved
Feb 2026
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
3/8 — Basic
RYBREVANT FASPRO by Johnson & Johnson is met. Approved for metastatic nsclc with egfr exon 19 deletions, exon 21 l858r substitution mutations, whose disease has progressed on and 1 more indications. First approved in 2026.
Drug data last refreshed 18h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYBREVANT FASPRO is a bispecific antibody (amivantamab) combined with a human recombinant hyaluronidase for subcutaneous administration. It targets EGFR and MET pathways and is designed for patients with specific solid tumors. The hyaluronidase component enables faster subcutaneous delivery compared to traditional IV infusions.
Launch
As a newly launched bispecific with subcutaneous convenience, this product has significant growth potential and will require robust commercial infrastructure and medical education teams.
Mechanism of Action
MET. In in vitro and in vivo studies, amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 19 deletions, exon 21 L858R substitutions, and exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the…
Indications (3)
Worked on RYBREVANT FASPRO at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.